Emerging Opportunities for Serotypes of Botulinum Neurotoxins
Open Access
- 6 November 2012
- Vol. 4 (11), 1196-1222
- https://doi.org/10.3390/toxins4111196
Abstract
Background: Two decades ago, botulinum neurotoxin (BoNT) type A was introduced to the commercial market. Subsequently, the toxin was approved by the FDA to address several neurological syndromes, involving muscle, nerve, and gland hyperactivity. These syndromes have typically been associated with abnormalities in cholinergic transmission. Despite the multiplicity of botulinal serotypes (designated as types A through G), therapeutic preparations are currently only available for BoNT types A and B. However, other BoNT serotypes are under study for possible clinical use and new clinical indications; Objective: To review the current research on botulinum neurotoxin serotypes A-G, and to analyze potential applications within basic science and clinical settings; Conclusions: The increasing understanding of botulinal neurotoxin pathophysiology, including the neurotoxin’s effects on specific neuronal populations, will help us in tailoring treatments for specific diagnoses, symptoms and patients. Scientists and clinicians should be aware of the full range of available data involving neurotoxin subtypes A-G.Keywords
This publication has 134 references indexed in Scilit:
- Insights into the Different Catalytic Activities of Clostridium NeurotoxinsBiochemistry, 2012
- Receptor Binding Enables Botulinum Neurotoxin B to Sense Low pH for Translocation Channel AssemblyCell Host & Microbe, 2011
- Studies of the Mechanistic Details of the pH-dependent Association of Botulinum Neurotoxin with MembranesJournal of Biological Chemistry, 2011
- Syntaxin Requirement for Ca2+-Triggered Exocytosis in Neurons and Endocrine Cells Demonstrated with an Engineered NeurotoxinBiochemistry, 2011
- Botulinum neurotoxin subtype A2 enters neuronal cells faster than subtype A1FEBS Letters, 2010
- Structural Analysis of Botulinum Neurotoxin Type G Receptor Binding,Biochemistry, 2010
- Glycosylated SV2 and Gangliosides as Dual Receptors for Botulinum Neurotoxin Serotype FBiochemistry, 2009
- Catalytic Properties of Botulinum Neurotoxin Subtypes A3 and A4Biochemistry, 2009
- Entering neurons: botulinum toxins and synaptic vesicle recyclingEMBO Reports, 2006
- Treatment of spasticity with botulinum toxin: A double‐blind studyAnnals of Neurology, 1990